Ronald Williams - Johnson Johnson Independent Director
| JNJ Stock | USD 148.53 1.03 0.69% |
Director
Mr. Ronald A. Williams is an Independent Director of the Company. He served as Chairman and Chief Executive Officer of Aetna Inc. from 2006 to 2010, and as Chairman from 2010 until his retirement in April 2011. He is also an advisor to the private equity firm, Clayton, Dubilier Rice, LLC. In addition, Mr. Williams serves on the boards of MIT Corporationrationration, Peterson Institute for International Economics, the Advisory Board of Peterson Center on Healthcare and is Vice Chairman of the Board of Trustees of The Conference Board. Previously, Mr. Williams served on President Obama Management Advisory Board from 2011 to January 2017, as Chairman of the Council for Affordable Quality Healthcare from 2007 to 2010, and as Vice Chairman of The Business Council from 2008 to 2010. since 2011.
| Age | 71 |
| Tenure | 13 years |
| Address | One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Ronald Williams Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ronald Williams against Johnson Johnson stock is an integral part of due diligence when investing in Johnson Johnson. Ronald Williams insider activity provides valuable insight into whether Johnson Johnson is net buyers or sellers over its current business cycle. Note, Johnson Johnson insiders must abide by specific rules, including filing SEC forms every time they buy or sell Johnson Johnson'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ronald Williams over six months ago Acquisition by Ronald Williams of 467 shares of Boeing subject to Rule 16b-3 | ||
Ronald Williams over six months ago Acquisition by Ronald Williams of 1428 shares of Johnson Johnson subject to Rule 16b-3 | ||
Ronald Williams over six months ago Acquisition by Ronald Williams of 258 shares of Boeing subject to Rule 16b-3 | ||
Ronald Williams over six months ago Acquisition by Ronald Williams of 498 shares of Boeing subject to Rule 16b-3 |
Johnson Johnson Management Efficiency
The company has Return on Asset of 0.0833 % which means that on every $100 spent on assets, it made $0.0833 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1831 %, implying that it generated $0.1831 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Johnson Johnson's Return On Tangible Assets are relatively stable compared to the past year. Return On Capital Employed is expected to hike to 0.26 this year, although the value of Return On Assets will most likely fall to 0.14. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Kilts | Pfizer Inc | 71 | |
| Dan Littman | Pfizer Inc | 68 | |
| Franklyn Prendergast | Eli Lilly and | 70 | |
| Thomas Cech | Merck Company | 72 | |
| Frank Herringer | Amgen Inc | 74 | |
| Karen Walker | Eli Lilly and | 59 | |
| Judith Pelham | Amgen Inc | 69 | |
| William Kaelin | Eli Lilly and | 63 | |
| Gerald Storch | Bristol Myers Squibb | 64 | |
| Harish Manwani | Gilead Sciences | 64 | |
| Peter Arduini | Bristol Myers Squibb | 56 | |
| Roy Roberts | AbbVie Inc | 69 | |
| Togo West | Bristol Myers Squibb | 72 | |
| Stephen Sanger | Pfizer Inc | 69 | |
| Robert Williams | Amgen Inc | 69 | |
| Theodore Samuels | Bristol Myers Squibb | 66 | |
| Rebecca Henderson | Amgen Inc | 57 | |
| Gregory Garland | Amgen Inc | 60 | |
| Per WoldOlsen | Gilead Sciences | 70 | |
| Frank Biondi | Amgen Inc | 70 | |
| Rebecca Roberts | AbbVie Inc | 68 | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0833 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
| Duane Arsdale, Treasurer | ||
| Mary Coleman, Independent Director | ||
| Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
| Jasmina Brooks, President Webster | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Nadja West, Independent Director | ||
| Mark Larkins, Worldwide Secretary | ||
| Vanessa Broadhurst, Executive Vice President Global Corporate Affairs | ||
| Louise Mehrotra, Vice President Investor Relations | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Tom Cavanaugh, Company Medicine | ||
| D Davis, Independent Director | ||
| Anne Mulcahy, Lead Independent Director | ||
| Ian Davis, Independent Director | ||
| Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee | ||
| Mark Weinberger, Independent Director | ||
| A Washington, Independent Director | ||
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
| William Perez, Independent Director | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Executive CFO | ||
| Michael Bodner, Global Recovery | ||
| Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Mary Beckerle, Independent Director | ||
| Darius Adamczyk, Independent Director | ||
| Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee | ||
| Scott Davis, Director | ||
| Hani Abouhalka, Company Digital | ||
| Ahmet Tezel, Group RD | ||
| Robert Decker, Controller Officer | ||
| Mathai Mammen, Executive Vice President Pharmaceuticals, R&D | ||
| Timothy Schmid, Executive MedTech | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer | ||
| James Swanson, Executive Vice President, Chief Information Officer | ||
| Hubert Joly, Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health | ||
| Jessica Moore, Vice Relations | ||
| Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Celine Martin, Group CSS | ||
| Eugene Washington, Independent Director | ||
| Elizabeth Forminard, Executive Counsel | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Guy MD, Group EMEA | ||
| Susan Lindquist, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0833 | ||||
| Profit Margin | 0.47 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 367.76 B | ||||
| Shares Outstanding | 2.41 B | ||||
| Shares Owned By Institutions | 71.21 % | ||||
| Number Of Shares Shorted | 15.94 M | ||||
| Price To Earning | 24.69 X | ||||
| Price To Book | 5.17 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Johnson Johnson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.106 | Dividend Share 4.76 | Earnings Share 7.43 | Revenue Per Share 34.402 | Quarterly Revenue Growth (0.14) |
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.